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Abstract 
Purpose  
There has been a strong biological plausibility for a causal role of reactive oxygen species 
in cardiovascular disease pathology. However, randomized clinical trials of antioxidants showed 
no association between antioxidant intake and reduced risk of CVD mortality nor morbidity. To 
date, there has been no direct epidemiological evidence linking oxidative status to subclinical 
atherosclerosis progression. We examined prospective relationships between oxidative status 
(urinary F2-Isoprostanes) and subclinical atherosclerosis (common/internal carotid intima-media 
thickness) in the Insulin Resistance Atherosclerosis Study cohort (N=857) to determine if 
elevated systemic levels of F2-isoprostnaes are directly correlated with progression in subclinical 
atherosclerosis. 
Methods 
This study utilized data from the Insulin Resistance Atherosclerosis Study (IRAS), a 
prospective cohort study that was designed to examine the relationships between insulinemia, 
glycemia, insulin resistance, and cardiovascular risk in a racially and metabolically diverse 
population including African Americans, non-Hispanic whites, and Hispanics between 40-69 
years of age at baseline 27.  Between October 1992 and April 1994, 1625 men and women were 
recruited to participate in the study and followed up after 5 years27. Four urinary F2-isoprostane 
isomers were quantified at baseline using liquid chromatography/tandem mass spectrometry and 
were summarized as a composite F2-isoprostane index, which was used as a marker for oxidative 
status. Linear and logistic regression were used to assess the relationship between F2-
isoprostanes and the outcome of interest, subclinical atherosclerosis, measured by common 
carotid artery intima-media thickness (CCIMT) as well as internal carotid artery intima-media 
thickness (ICIMT). CCIMT and ICIMT were assessed at baseline and at the follow-up 
examinations. In logistic regression models, progression of CCIMT and ICIMT was defined as a 
>15% change during the follow-up examination and the main exposure was the baseline F2-
isoprostane index. The covariates included age, sex, ethnicity and baseline BMI, smoking status, 
and systolic blood pressure (SBP). In linear regression models, natural log transformed 
CCIMT/ICIMT at follow-up were dependent variables and the baseline F2-isoporstane index 
was the main exposure with the baseline natural log transformed CCIMT/ICIMT and the same 
covariates included as predictors. 
 
Results 
After adjustment for age, sex, ethnicity, BMI status, smoking status and systolic blood 
pressure, logistic regression models showed that F2-isoprostanes had an inverse association with 
CCIMT progression (OR= 0.76, 95% CI [0.58, 1.01]) and no association with progression of 
ICIMT (OR = 0.94, 95% CI [0.76, 1.17]). Linear regression also showed a tendency of inverse 
relationships between F2-isoprostane index and change in CCIMT and ICIMT:  beta-coefficients 
for F2-isoprostane index were -0.014, 95% CI (-0.029,0.0006)] and -0.0021, 95% CI (-
0.030,0.026), in the models predicting change in CCIMT and ICIMT, respectively. 
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Conclusion 
The result from this study suggest that elevated levels of F2-isoprostanes do not directly 
predict subclinical atherosclerosis progression. Future studies are needed to get a better 
understanding of the different forms of oxidative status markers and their influence on 
cardiovascular disease risk.   
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Introduction 
Purpose of Study 
 
  Cardiovascular disease (CVD) is an umbrella term used to describe heart conditions that 
involve narrowed or blocked blood vessels mainly caused by atherosclerosis that can lead to 
adverse health outcomes such as heart attacks, strokes and angina1. Cardiovascular disease is the 
leading cause of death in the United States accounting for 610,100, 1 out of 4, deaths every 
year2. Understanding symptoms, indicators, and exposures increasing the risk of CVD is 
important for early detection and prevention. One way to detect early signs of CVD risk is to 
assess subclinical atherosclerosis. Subclinical atherosclerosis is an early indicator of 
atherosclerotic risk and timely recognition can slow or prevent progression to clinical 
manifestation of CVD3.  Previously published studies suggested that oxidative stress promotes 
atherosclerosis and could be an indicator of increased risk for CVD4. Oxidative stress can be 
assessed using different biomarkers such as F2-isoprostanes, malondialdehyde, nitrotyrosine, S-
glutathionylation, myeloperoxidase, oxidized LDL, and serum antioxidant capacity in relation to 
CVD. However, there is a gap in the literature on whether oxidative stress induces the 
progression of subclinical atherosclerosis. The aim for this study is to analyze the association 
between oxidative status assessed by urinary levels of F2-isoprostanes (oxidative status 
biomarker) and progression of subclinical atherosclerosis assessed by carotid intima-media 
thickness (biomarker for subclinical atherosclerosis). Our main research question is to determine 
whether elevated levels of urinary F2- isoprostanes predict increase in the carotid intima-media 
thickness. This study is a novel analysis with the goal to expand the current knowledge of the 
pathology of atherosclerosis with the intention of developing a better understanding of 
measurements for primary prevention of CVD. 
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Literature review 
Atherosclerosis  
Atherosclerosis, a specific type of arteriosclerosis, is a chronic-inflammatory disease that is 
defined by the narrowing of medium and large sized arteries due to the accumulation of fats and 
inflammatory cells20. While the exact cause of atherosclerosis is not fully understood it is 
believed to be caused by various risk factors such as high blood pressure, high cholesterol, high 
triglycerides, smoking, inflammation, obesity, and diabetes7. According to Howard, et al. current 
smokers had a 50% increase in atherosclerosis progression rate compared to those that never 
smoked (43 µm vs 28.7 µm) while past smokers had a 25% increase in atherosclerosis 
progression compared to those that never smoked (35.8 µm vs 28.7 µm) assessed by common 
carotid intima-media thickness as a surrogate measure of atherosclerosis46.  
The factors mentioned previously can cause damage to the endothelium of the arteries and 
allow fat cells to enter into the artery wall7. On occasions, when the body tries to repair the 
injured site white blood cells, fats, and cholesterol clump together at the injury site and form 
plaque7. Eventually this plaque build-up can harden in the artery wall and start to restrict blood 
flow preventing oxygen and other important nutrients from reaching vital organs and tissues in 
the body, causing them to function poorly.   
Atherosclerosis is a slow progressive disease that can start in childhood, but symptoms are 
usually not observed until middle or older age. Sometimes plaque build-up can break off from 
the artery wall and enter the blood stream. This can cause pain in the chest or in the legs when 
excreting oneself8. Other symptoms can include shortness of breath, fatigue, muscle weakness, 
and confusion however, not having symptoms is also common. A cross-sectional study with 262 
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participants with no signs or symptoms of atherosclerosis concluded that 52% had some sort of 
atherosclerosis, 85% of those 50 are older had atherosclerosis, and that it was present in 17% of 
children61. Due to the fact that there are sometimes no symptoms involved with atherosclerosis it 
is important to partake in prevention methods such as keeping track of blood pressure and 
cholesterol levels, eating healthy, exercising regularly, stop smoking, and decreasing alcohol 
intake to ensure decreased odds of getting atherosclerosis. Although there have been studies that 
showed decrease in plaque formation31,32,33, Plaques usually do not go away after they are 
formed, so medications for high blood pressure and high cholesterol along with lifestyle changes 
are the best treatments to stop or slow the progression of plaque growth8. If plaque build-up is 
not properly managed atherosclerosis can lead to blood clots and cause cardiovascular events 
such as stoke, heart attacks, and angina. Due to this, it is important to detect sign of 
atherosclerosis as early as possible and one way to assess this is through subclinical 
atherosclerosis measurements. 
 
Subclinical Atherosclerosis  
Subclinical atherosclerosis is an early indicator of atherosclerotic risk before the 
manifestation of clinical symptoms and is believed to be an important tool for early detection of 
CVD risk6. Various techniques can be utilized to measure subclinical atherosclerosis. For 
example, arterial stiffness can be measured via pulse wave velocity, whereas other measures 
include ankle-brachial index (ABI), and carotid intima-media thickness (CIMT)6. 
Arterial stiffness is the result of alterations of the arterial structure and function coupled 
with the deposition of collagen, calcium and loss of elastic matrix 6. Arterial stiffness has been 
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shown to play an important role in the progression of atherosclerosis and CVD. There is a variety 
of ways to measure arterial stiffness, but the most efficient marker was deemed to be pulse wave 
velocity which is the time required for the pressure wave to travel between two regions in the 
vasculature6.  
Ankle-Brachial Index (ABI) is a ratio of the systolic blood pressure measured at the ankle 
to the systolic blood pressure in the upper arm. It is also a strong predictor for CVD events. ABI 
measurements less than 0.90 were shown to have a strong association with CVD events, HR, 
1.20; 95% CI, 1.08 to 1.326. Other studies have shown that having a low ABI compared to a 
normal ABI which is between 1.10-1.14 was an indication of a 2-3-fold increased risk of carotid 
atherosclerosis6. 
Carotid artery intima-media thickness 
(CIMT) is the measurement performed at the 
carotid arteries. Thickening of the arteries is due to 
the onset of atherosclerosis, the accumulation of 
fatty deposits and inflammatory cells in the walls 
of the arteries.  These arteries carry oxygen rich 
blood from the heart to the head, face, and brain. 
CIMT can be measured either through the common 
carotid intima-media thickness (CCIMT) or the 
internal carotid intima-media thickness (ICIMT). 
The common carotid arteries are the ones that go from the heart to the neck on both sides and 
once they reach the neck, they branch off to form the internal carotid artery (inner side of the 
neck) and the external carotid artery (outer side of the neck). The external carotid artery supplies 
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blood to the face, scalp, and skull while the internal carotid artery supplies blood to the brain. 
The thickness of the two innermost layers of the carotid artery, called the tunica intima and 
tunica media, are used to detect atherosclerosis (Shown in Figure 2). Because the carotid arteries 
are large arteries close to the surface of the skin the two layers are able to be measured using 
non-invasive B-mode ultrasounds. Ultrasound measurements are usually taken at three different 
places, from the near and far walls of common carotid arteries, the carotid bifurcation, and the 
proximal internal carotid arterial segments49. Once the ultrasound is complete the test will 
generate the measurements and a risk assessment49. 
 
The average CIMT is 0.40 
to 0.50 mm for children 
and 0.70 mm or more for 
adults6. There have been 
some inconsistencies with 
regard to using CIMT as a 
predictor of CVD risk; 
however, the meta-analysis 
performed on previous 
studies showed that CIMT 
was associated with first 
myocardial infraction and 
stroke along with other cardiovascular events6. However, to deal with these uncertainties it is 
hypothesized that CIMT combined with carotid plaque assessment is a better predictive model of 
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CVD events6. The most common location of atherosclerotic plaque buildup is in the inner wall of 
the carotid bifurcation area49. Carotid plaques are detected through ultrasound and is defined as 
an area of the artery wall that is thicker than the surrounding CIMT area by a width of 0.5 mm or 
a CIMT greater than 1.550-51 as demonstrated in figure 3 below. One step that is believed to be 
important in the pathogenesis of atherosclerosis is the oxidation of low-density lipoproteins and 
understanding this mechanism may lead to discovering ways to prevent or slow atherosclerosis 
progression9. 
 
Lipid Peroxidation, F2-Isoprostanes, and Oxidative Status 
Lipoprotein is a substance that is responsible for carrying cholesterol, triglycerides, and free 
fatty acids throughout the body10. There are four different classes of plasma lipoproteins 
substances, chylomicrons, very-low density lipoproteins (VLDL), low-density lipoproteins 
(LDL), and high-density lipoprotein (HDL)11. HDL collects cholesterol from peripheral tissue, 
delivering cholesterol back to the liver for excretion12. HDL is considered to be a beneficial 
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lipoprotein because it plays an important role in prevention of cardiovascular disease12. Research 
has shown that high circulating HDL levels correlate with low rates of atherosclerosis12. Gordon 
et al. showed that HDL is an independent cardiovascular risk factor and that the increase of HDL 
by only 10 mg·L−1 resulted in a risk reduction of 2–3%52. Di’Angelantonio et al. showed that 
those in the higher quantiles of HDL level had lower rates of coronary heart disease (CHD) per 
1000 person years vs those in the lower quantiles for HDL levels (2.4 per 1000 p-yrs. vs 6.4 per 
1000 p-yrs.) with a hazard ratio of 0.78 (95% CI, 0.74-0.82)53. Additionally, Di’Angelantonio et 
al. examined LDL levels and saw that those with high circulating LDL levels had a higher rate of 
CHD per 1000 person years compared to those with low levels (6.7 per 1000 p-yrs. vs 2.3 per 
1000 p-yrs.) with a hazard ratio of 1.50 (95% CI, 1.38-1.62)53. These findings may be due to the 
antioxidant and anti-inflammatory properties seen in normal functioning HDL12. Normal 
functioning HDL is known to prevent oxidation of LDL as well as prevent the inflammatory 
process seen after the oxidation12.   
Low-density lipoprotein, LDL, on the other hand is known to have a direct association with 
cardiovascular risk12. LDL particles are formed through the hydrolysis of intermediate-density 
lipoprotein and contain a high level of cholesterol12. LDL particles can be modified12. One type 
of modification that is an important step in the pathogenesis of atherosclerosis, is oxidation of 
LDL, also called lipid peroxidation12. The oxidation process can happen in many parts of the 
LDL however polyunsaturated fatty acids are the most susceptible constituents of LDLs due to 
the multiple double bonds within the structure. Lipid peroxidation of LDL is the result of a 
reaction between LDL and molecules called reactive oxygen species (ROS). ROS are a type of 
free radical mainly created by the mitochondria with the most common form being superoxide53. 
The enzymes used in complex I, complex III, as well as glycerol-3-phosphate dehydrogenase of 
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the electron transport chain are what creates the reactive oxygen species53. Reactive oxygen 
species are highly reactive and having a large amount of circulating ROS can lead to oxidative 
stress which is known to cause damage to proteins, DNA, and RNA53. It is hypothesized that 
these molecules play an integral role in the pathogenesis of cancer, cardiovascular disease, and 
insulin resistance. Interacting with the ROS, LDL lipids form a variety of lipid oxidation 
products, which subsequently modifies the apolipoprotein part of the LDL9. The most common 
ROS that have shown to be associated with atherosclerosis are -O2, OONO-, H2O2, HO, and O225.   
The modified LDL apolipoprotein has altered receptor affinity, making it capable to bind 
with scavenger receptors on 
macrophages in the walls of 
the arteries in an 
uncontrolled manner9. 
Macrophages are cells that 
play an important role in 
immune function and are 
believed to play an important 
role in atherosclerosis 
progression26. Once the LDL 
particles are phagocytized into the macrophages, they become foam cells and form fat buildup in 
the artery wall leading to atherosclerosis4. One substance that is used to assess lipid peroxidation 
levels in vivo are markers of lipid peroxidation called F2-isoprostanes26.  
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Prostaglandin like compounds also known as F2-isoprostanes are substances that are non-
enzymatically formed via lipid peroxidation of arachidonoyl radicals (13,24). Arachidonic acid is a 
type of unsaturated 
fatty acid found in 
the plasma 
membrane, where it 
is bound to 
phospholipids34. 
  F2-
isoprostanes increase 
in response to 
oxidant injury and is 
known to be the most efficient measurement of lipid peroxidation in vivo13. Elevated levels of 
F2-isoprotanes are observed in diseases associated with atherosclerosis leading to the hypothesis 
that there is a strong link between lipid peroxidation and atherosclerosis14. F2-isoprostanes are 
easily measured through non-invasive measure such as collections of urine samples. The most 
common isomer of F2-isoprostanes used in human studies to measure oxidative stress is 8-iso-
prostagladin-F223. As with all urinary biomarkers, urinary levels of F2-isoprostanes are 
standardized by urinary creatinine to account for inter-individual variability in urine diluteness. 
Unlike ROS which are very reactive and unstable molecule, F2-isoprostanes, their biological 
“footprints” present chemically stable molecules, which is an important consideration in 
choosing biomarkers for human studies. For example, 15-series F2-isoprostane concentration 
remained unchanged in urine samples stored at –20°C14 and they also remained unchanged when 
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urine specimens were left at room temperature overnight14. It is also important to note that 
urinary F2-isoprostanes levels are not dependent on diet and are not modified by lipid 
consumption, giving more evidence of its reliability of a good biomarker of in vivo lipid 
peroxidation14. F2-isoprostanes as a marker for oxidative stress can also be used as a tool to 
assess the effects of various antioxidants to see which ones are most effective in achieving 
homeostasis in oxidative status15.  Antioxidants may help to combat LDL oxidation by protecting 
cells against ROS-induced damage4. 
 
Antioxidant Trials 
Oxidative stress is caused by the imbalance of oxidant species and antioxidant species. 
As mentioned above F2-isoprostanes are used as a marker of oxidative stress and can also be 
used to assess antioxidants effectiveness 16. Natural antioxidants such as vitamin A, vitamin E, 
flavonoids, and carotenoids are believed to play an important role in atherosclerosis prevention16. 
Although it is believed that an increase in antioxidant intake may reduce the risk of 
atherosclerosis, by preventing oxidation of LDL, randomized control  antioxidant trials showed 
otherwise16,22,23. Some randomized control trials showed antioxidant supplementation was not 
associated with decrease in atherosclerosis risk and in some cases may actually be associated 
with higher increase risk of atherosclerosis events and CVD death (16,21,22). A meta-analysis by 
Cherubini et al. showed that the PHS study found that B-Carotene had no effect on CV death or 
all-cause mortality16.  Three additional studies (PPP, SECURE, and VEAPS) showed that 
Vitamin E had a neutral effect of the progression of common carotid artery IMT indicating that 
Vitamin E supplementation was not associated with decrease in atherosclerosis progression. 
Additionally, the CARET study (the Beta-Carotene and Retinol Efficacy Trial) showed that B-
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carotene and Vitamin A increased all-cause mortality, and that these supplements also increased 
CV death16. The Cherubini et al. meta-analysis also showed four different random control trials 
analyzing the association between antioxidants and secondary prevention of atherosclerosis and 
cardiovascular disease. The studies found no benefits in taking antioxidant supplements16.The 
negative and neutral results from these random control trials pose a question of whether 
increased ROS levels in humans stimulates progression of atherosclerosis 
There have been cross-sectional and cohort studies that showed a correlation between 
increased natural antioxidant intake and decreased atherosclerosis risk (17,18,19) however, the 
inverse association in these studies may have been compromised by other chemicals found in 
foods that contributed to decrease in atherosclerosis risk16,18,19. It is hypothesized that natural 
antioxidants may only be an effective treatment for those with high oxidative stress levels or 
those that have a depletion of natural antioxidants18,19. The true relationship between oxidative 
stress and atherosclerosis is not currently known and further studies are necessary to test the 
efficacy of antioxidants on CVD prevention before any conclusions or recommendations can be 
made. In this study we will examine the association of F2-isoprostanes and subclinical 
atherosclerosis in an attempt to understand the connection between the two. 
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Research Methods and Procedures 
Study Population 
This analysis used the Insulin Resistance Atherosclerosis Study (IRAS) to understand the 
association between oxidative status and subclinical atherosclerosis. The IRAS is a prospective 
cohort study that was designed to examine the relationships between insulinemia, glycemia, 
insulin resistance, and cardiovascular risk in a racially and metabolically diverse population 
including African Americans, non-Hispanic whites, and Hispanics 27.  Between October 1992 
and April 1994, 1625 men and women were recruited to participate in the study and followed up 
after 5 years27. The participants were between 40-69 years of age at baseline and were recruited 
from four different clinical centers to represent a range of glucose tolerance (impaired vs normal) 
and ethnicity27. 
 
Analytic Cohort 
Our analytical cohort included participants who were free of diabetes at baseline, 
underwent both – baseline and follow-up – examinations, and provided urine specimen at 
baseline (n=901).   Among them, several participants were excluded, because of unreliable 
measurements of urinary F2-isoprotsanes. After doing additional analysis on change in carotid 
intima-media thickness, it was determined that two participants were extreme outliers and were 
removed leaving a total of 855 participants eligible for the linear and logistic regression analysis. 
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Outcome of interest: subclinical atherosclerosis  
Carotid intima-media artery wall thickness (CIMT) was used as an indicator for 
subclinical atherosclerosis. CIMT was measured using B-mode ultrasonography at bassline26. 
The IRAS measured both CCIMT and ICIMT. For this study CCIMT was the primary outcome 
of interest and ICIMT was the secondary outcome of interest. 
 
Exposure of interest: F2-isoprotanes  
Four different urinary F2-isoprostanes were utilized in this study which included iPF (2 
alpha)-III, 2,3-dinor-iPF (2 alpha)-III, iPF (2 alpha)- VI, and 8,12-iso-iPF (2 alpha)-VI. Urinary 
concentration of F2-isoprostane isomers (ng) adjusted for mg urinary creatinine were used as 
indictors of oxidative status. The adjustment for creatinine is used to account for inter-individual 
variability in urine diluteness. The isomers were measured in samples of morning spot urine 
specimens at baseline. The specimens were stored at -70° C and quantified using liquid 
chromatography-tandem mass spectrometry28.  Creatinine was assayed using a fast electrospray 
ionization-tandem mass spectrometry method 28.  
The F2-isoprostane index is a variable that was previously created as a composite 
measurement of all four F2-Isoprostane isomers 30. The index was created using the formula 
[(X1𝑖 − M1)/SD1+(X2𝑖 − M2)/SD2+(X3𝑖 − M3)/SD3+(X4𝑖 − M4)/SD4]/4, where “𝑖” is a 
notation for a participant30. The values of four F2-isoprostanes species (X1–4) were standardized 
by subtracting estimated mean (M1–4) and divided by standard deviation (SD1–4)30. Previous 
studies have shown that the F2-isoprostane index is a good summary mean of the four F2-
isoprostane isomers29,30 
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Covariates 
Demographic factors included baseline age, gender, and ethnicity. Lifestyle risk factors 
for CVD included self-reported baseline smoking status (ever/never), and Body Mass Index 
(BMI), as weight in kilograms divided by height in meters squared. Glucose tolerance status was 
determined through a 75 g oral glucose tolerance test at baseline and at follow-up and classified 
according to the World Health Organization criteria60. Plasma lipoprotein measurements were 
obtained from fasting, single, fresh plasma samples by using Lipid Research Clinics methods60.  
To measure HDL levels, precipitation of apo B–containing lipoproteins with MnCl2 and heparin 
was utilized and the cholesterol content in the supernatant was measured in a separate 
autoanalyzer60. LDL cholesterol was calculated as the difference between the HDL cholesterol 
and the cholesterol from the bottom fraction of VLDL particles after it was isolated via 
ultracentrifugation60. Triglycerides were measured enzymatically after correction for free 
glycerol60.  
 History of CVD events at baseline was defined as a history or presence of at least one of 
the following conditions: self-reported stroke, angina, heart problems, myocardial infraction, or 
hypertension. Hypertension was determined by blood pressure measurements using standard 
mercury column sphygmomanometer. Three measurements were taking during the examinations 
at baseline and follow-up and the second and third measurement was used to determine 
hypertension29.  Hypertension was defined as a systolic blood pressure greater than 140 mm Hg 
and/or diastolic blood pressure greater than 90 mm Hg, and/or a current regimen of 
antihypertensive medications29 
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Statistical analysis 
 
All analysis was performed using SAS 9.3. For model building bivariate analyses 
examining the association between outcome or main predictor (Common and Internal CIMT/ F2-
isoprostane isomers) and categorical covariates were performed using the Wilcoxon and 
Kruskal-Wallis tests to test for possible confounders. Bivariate analyses examining the 
association between outcome or main predictor (Common and Internal CIMT/ F2-isoprostane 
isomers) and continuous covariates were performed using the Spearman correlation coefficient to 
test for possible confounders. To determine whether elevated levels of oxidative status can 
predict progress in subclinical atherosclerosis, we first dichotomized change in CCIMT and 
ICIMT into two categories. Taking into account measurement error of IMT based on previous 
studies, which is between 0.08 mm and 0.20 mm55, we considered > 15% increase in CIMT 
during the 5-year follow-up as the indicator of progression in subclinical atherosclerosis. No 
change or decrease in CIMT during the observation period was considered as lack of progression 
in subclinical atherosclerosis. Those that had increased CIMT were considered cases, whereas 
those with no CIMT increase were considered non-cases.  A total of 178 participants were 
classified as cases with clear indication of subclinical atherosclerosis using CCIMT and 243 as 
cases using ICIMT.  
Univariate logistic regression examined the crude relationship between CIMT and the F2-
isoprostane isomers. Multivariate logistic regression examined the relationship between CIMT 
and F2-isoprostane isomers after adjustment for age, sex, ethnicity, IGT status, and BMI. To 
verify the result from the logistic regression, we analyzed changes in CCIMT and ICIMT as 
continuous variables using linear regression. Natural log transformation of the CIMT data was 
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utilized to address skewness in the data. The outcome was modeled as follow-up log transformed 
CIMT, the main exposure was the F2-isoprostane index, and the predictors included baseline 
CIMT (log transformed), and the following covariates: age, sex, ethnicity, smoking status, BMI, 
and systolic blood pressure. 
A Sensitivity analysis was performed to address the influence of cardiovascular disease 
history as a possible intermediate variable. Those that had history of CVD were excluded from 
the analysis and additional logistic regression analyses were performed. At baseline 403 
individuals were considered to have a history of CVD leaving a total of 454 participants eligible 
for the sensitivity analysis. 
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Results 
Baseline Descriptive Characteristics 
 
In this study population with 857 metabolically and ethnically diverse participants, the 
average age was 54.56 and there were more females (57.64 %) than males (42.36). There were 
slightly more non-Hispanic whites (40.02%) in the study population, compared to Hispanics 
(32.21%) and non-Hispanic blacks (27.77%) which can be seen in Table 1. About one-third of 
the study population had impaired glucose tolerance (32.44%) and about half had a history of 
CVD events or hypertension (47.03%) at baseline (table 1). 
Table 1. Descriptive Statistics for Baseline Characteristics   
Variable  Level N (%) N= 857 
Ethnicity  Non-Hispanic Black 
Hispanic  
Non-Hispanic White 
238 (27.77) 
276 (32.21) 
343 (40.02) 
 
Sex Male  
Female 
363 (42.36) 
494 (57.64) 
IGT-Status Normal  
IGT 
Diabetes 
579 (67.56) 
278 (32.44) 
0 
CVD Events Yes  
No 
403 (47.03) 
454 (52.97) 
Smoking Status Never 
Past/Current 
398 (46.44) 
459 (53.56) 
 
Age (years) Mean 
Median  
Std Dev 
IQR 
54.56 
54.00 
8.31 
14 
BMI (kg/m2) Mean 
Median  
Std Dev 
IQR 
28.46 
27.29 
5.66 
5.75 
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Baseline Characteristics for Exposure and Outcomes of Interest 
The main outcome of interest, common carotid artery intima-media thickness (CCIMT), 
and the secondary outcome of interest, internal carotid artery intima-media thickness (ICIMT), 
differed slightly at baseline and follow up. Mean ICIMT was measured to be greater than mean 
CCIMT at baseline (0.91 mm vs 0.80 mm) and at follow up (1.01 mm vs 0.84mm) respectively 
(Table 2). The mean levels of F2-isoprostane in the study population varied among the four 
isomers ranging from 0.25 ng/mg creatinine (CN) up to 6.48 ng/mg creatinine (CN) as shown in 
Table 2. 
 
Table 2. Descriptive Statistics for Outcomes (CCIMT, ICIMT) and Predictors (F2-Isoprostanes) 
Variables (Carotid Artery IMT) Mean (SD) N=857 Median (IQR) N=857 
Common Carotid Artery IMT-Baseline (mm) 0.80 (0.22) 0.76 (0.20) 
 
Common Carotid Artery IMT-Follow-up (mm) 0.84 (0.25) 0.78 (0.22) 
Internal Carotid Artery IMT-Baseline (mm) 0.91 (0.40) 0.79 (0.25) 
Internal Carotid Artery IMT-Follow-up (mm) 1.01 (0.55) 0.82 (0.33) 
Variables (F2-Isoprostanes)  Mean (SD) Median (IQR) 
 
2,3-dinor-iPF(2a)-III, ng/mg CN 
4.35 (3.00) 3.71 (2.74) 
 
iPF(2a)- III, ng/mg CN 
0.25 (0.19) 0.20 (0.17) 
 
 
iPF(2a)- IV, ng/mg CN 
6.48 (4.16) 5.37 (4.18) 
 
8,12-iso-iPF(2a)-IV, ng/mg CN 
4.15 (2.87) 3.46 (2.79) 
F2-isoprostane Index, ng/mg CN -0.06 (0.82) -0.23 (0.83) 
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Confounder Analysis 
To identify potential confounders, we selected variables that are known to be associated 
with subclinical atherosclerosis and/or oxidative status and examined their crude association with 
the outcomes (Table 3) and primary predictor (Table 4). The variables that were associated with 
CCIMT/ ICIMT included sex, ethnicity, smoking status, and IGT status. Males had higher 
CCIMT/ ICIMT than females, non-Hispanic blacks had higher CCIMT/ ICIMT than both non-
Hispanic whites and Hispanics. Those with IGT had greater CCIMT/ ICIMT compared to those 
with normal glucose tolerance (Table 3) at baseline. For IGT status at follow-up, those that were 
diagnosed with diabetes had greater CCIMT/ICIMT compared to those with normal glucose 
tolerance and those with IGT.  Additionally, those that currently smoke or used to smoke had 
higher CCIMT/ ICIMT levels than those that never smoked. Based on the Spearman correlation 
age, BMI, LDL, and systolic blood pressure are associated with CCIMT/ ICIMT progression and 
has a direct correlation with CCIMT/ ICIMT indicating that as age, BMI, LDL, and systolic 
blood pressure increases so does CCIMT/ ICIMT levels (Table 3). 
  Examining crude associations between the F2-isoprostane index and suspected 
confounders in Table 4, we found that sex, ethnicity, smoking status, and IGT status at follow-up 
were associated with baseline oxidative status. Females, Hispanic, those with a history of 
smoking, and those with impaired glucose tolerance had higher levels of systemic F2-isoprotanes 
(Table 4). BMI and HDL were associated with and directly correlated with oxidative status. Age 
was associated with and inversely correlated with F2-isoprostanes.   
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Table 3.  Association between Outcomes, CCIMT and ICIMT, and Characteristics of Interest 
Variables CCIMT 
Baseline, mm 
 
Median (IQR) 
CCIMT follow-up, 
mm 
 
Median (IQR) 
ICIMT Bassline, 
mm 
 
Median (IQR) 
ICIMT follow-up, 
mm 
 
Median (IQR) 
Sex 
Male 
Female 
P-value* 
 
0.80 (0.23) 
0.74 (0.20) 
<.0001 
 
0.83 (0.26) 
0.76 (0.18) 
<.0001 
 
0.82 (0.29) 
0.76 (0.22) 
<.0001 
 
0.87 (0.44) 
0.79 (0.27) 
<.0001 
Ethnicity 
Black 
Hispanic 
White 
P-value* 
 
0.81 (0.24) 
0.73 (0.18) 
0.76 (0.19) 
<.0001 
 
0.83 (0.24) 
0.73 (0.19) 
0.80 (0.22) 
<.0001 
 
0.83 (0.22) 
0.74 (0.18) 
0.79 (0.34) 
<.0001 
 
0.85 (0.30) 
0.77 (0.26) 
0..84 (0.43) 
<.0001 
CVD Events (Baseline) 
Yes 
No 
P-value* 
 
 
0.82 (0.23) 
0.73 (0.16) 
<.0001 
 
 
0.83 (0.25) 
0.75 (0.20) 
<.0001 
 
 
0.80 (0.31) 
0.77 (0.22) 
0.012 
 
 
0.85 (0.43) 
0.80 (0.25) 
<.0001 
IGT-Status 
Normal 
IGT 
Diabetes 
P-value* 
 
0.75 (0.22) 
0.80 (0.20) 
N/A 
0.0005 
 
0.76 (0.21) 
0.80 (0.25) 
0.84 (0.28) 
<.0001 
 
0.78 (0.24) 
0.79 (0.28) 
N/A 
0.15 
 
0.80 (0.30) 
0.83 (0.37) 
0.88 (0.42) 
0.032 
Smoking Status 
Never 
Past/Current 
P-value* 
 
0.74 (0.21) 
0.78 (0.21) 
0.0082 
 
 
 
0.76 (0.19) 
0.80 (0.26) 
0.0008 
 
 
0.77 (0.23) 
0.79 (0.31) 
0.0052 
 
0.80 (0.24) 
0.85 (0.46) 
0.0002 
LDL  
Spearman correlation 
P-Value 
 
0.15 
<.0001 
 
 
0.084 
0.0158 
 
 
0.18 
<.0001 
 
 
0.05 
0.2005 
 
HDL  
Spearman correlation 
P-Value 
 
0.0021 
0.9531 
 
 
-0.070 
0.048 
 
 
-0.049 
0.18 
 
 
 
-0.061 
0.083 
 
Age (baseline years) 
Spearman correlation 
P-Value 
 
0.37 
<.0001 
 
0.36 
<.0001 
 
0.18 
<.0001 
 
 
 
0.22 
<.0001 
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BMI (kg/m2) 
Spearman correlation 
P-Value 
 
0.14 
0.0001 
 
0.17 
<.0001 
 
0.06 
0.11 
 
0.0015 
0.97 
Systolic Blood Pressure  
 
Spearman correlation 
 
p-value 
 
0.42 
<.0001 
 
 
 
 
0.39 
<.0001 
 
 
 
0.12 
0.0010 
 
 
 
0.16 
 
<.0001 
*Wilcoxon and Kruskal-Wallis test performed  
 
 
 
 
 
Table 4. Association between Baseline F2-isoprotanes and Characteristics of Interest 
Variables  
2,3-dinor-
iPF(2a)-III 
 
Median (IQR) 
 
iPF(2a)- III 
 
 
Median 
(IQR) 
 
iPF(2a)- IV 
 
 
Median (IQR) 
 
8,12-iso-
iPF(2a)-IV 
 
 
Median (IQR) 
 
F2-isoprostane 
Index  
 
Median (IQR) 
Sex 
Male 
Female 
P-value* 
 
2.95 (1.84) 
4.47 (3.23) 
<.0001 
 
0.16 (0.12) 
0.24 (0.20) 
<.0001 
 
4.22 (2.79) 
6.39 (4.76) 
<.0001 
 
3.20 (2.13) 
3.62 (3.33) 
0.0038 
 
-0.43 (0.53) 
0.03 (1.00) 
<.0001 
Ethnicity 
Black 
Hispanic 
White 
P-value* 
 
3.23 (2.29) 
4.46 (3.15) 
3.56 (2.70) 
<.0001 
 
0.16 (0.14) 
0.25 (0.20) 
0.20 (0.16) 
<.0001 
 
4.34 (2.86) 
6.91 (4.68) 
5.37 (3.96) 
<.0001 
 
 
2.90 (2.08) 
4.03 (3.64) 
3.48 (2.35) 
<.0001 
 
 
-0.43 (0.60) 
008 (0.93) 
-0.25 (0.78) 
<.0001 
CVD Events (baseline) 
 
Yes 
No 
P-value* 
 
 
3.78 (2.63) 
3.69 (2.81) 
0.48 
 
 
0.19 (0.17) 
0.21 (0.17) 
0.10 
 
 
5.08 (3.66) 
5.78 (4.62) 
0.0017 
 
 
3.35 (2.69) 
3.53 (2.88) 
0.063 
 
 
-0.28 (0.83) 
-0.13 (0.85) 
0.066 
IGT-Status (baseline) 
Normal 
IGT 
Diabetes 
P-value* 
 
3.67 (2.55) 
4.08 (3.09) 
N/A 
0.022 
 
 
0.20 (0.18) 
0.20 (0.16) 
N/A 
0.54 
 
5.39 (3.98) 
5.29 (5.17) 
N/A 
0.93 
 
3.32 (2.68) 
3.56 (2.95) 
N/A 
0.21 
 
-0.23 (0.78) 
-0.20 (0.93) 
N/A 
0.28 
Smoking Status (baseline) 
Never 
Past/Current 
P-value* 
 
3.70 (2.91) 
3.74 (2.61) 
0.041 
 
0.20 (0.17) 
0.21 (0.17) 
<.0001 
 
 
 
5.49 (4.68) 
5.28 (4.00) 
0.0105 
 
 
3.52 (2.93) 
3.40 (2.64) 
0.12 
 
-0.18 (0.80) 
-0.23 (0.83) 
0.0003 
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LDL (baseline) 
Spearman correlation 
P-Value 
 
-0.072 
0.039 
 
 
-0.096 
0.0055 
 
 
-0.044 
0.20 
 
 
-0.024 
0.49 
 
 
-0.067 
0.054 
 
HDL (baseline) 
Spearman correlation 
P-Value 
 
0.11 
0.0013 
 
 
0.13 
0.0002 
 
 
0.17 
<.0001 
 
 
0.018 
0.60 
 
 
0.13 
0.0001 
 
Age (baseline) 
Spearman correlation 
P-Value 
 
-0.031 
0.35 
 
-0.010 
0.76 
 
-0.033 
0.34 
 
-0.17 
<.0001 
 
-0.072 
0.036 
BMI (kg/m2) (baseline) 
Spearman correlation 
P-Value 
 
0.18 
<.0001 
 
0.0043 
0.89 
 
0.045 
0.18 
 
0.10 
<.0024 
 
 
0.10 
0.0034 
Systolic Blood Pressure 
(baseline) 
Spearman correlation 
 
p-value 
 
 
0.030 
0.39 
 
 
 
-0.035 
0.30 
 
 
 
 
-0.080 
0.023 
 
 
 
-0.038 
0.27 
 
 
 
-0.031 
0.36 
 
*Wilcoxon and Kruskal-Wallis test performed 
 
After considering the results in Tables 3 and 4, six of the total ten potential covariates 
were selected for the final linear and logistic regression analyses. The final model included sex, 
ethnicity, age, BMI, smoking status, and systolic blood pressure as confounders. 
Univariate and Multivariate Logistic Regression Analysis  
 
Logistic regression was used to estimate the association between oxidative status and 
progression in subclinical atherosclerosis. We found inverse association between baseline F2-
isoprostane levels and CCIMT progression (OR = 0.77, 95% CI [0.61-0.98]) before being 
adjusted for other covariates. This crude association indicated that the exposure, elevated F2-
isoprostanes in urine, are more likely to be found among non-cases (Table 5). After adjustment 
for the selected covariates F2-isoprostanes continue to have an inverse association with CCIMT 
(OR= 0.76 ,95% [0.58-1.01]). F2-isoprostanes were not associated with ICIMT before 
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adjustment (OR = 1.01, 95% CI [0.83-1.20]) or after adjustment (OR = 0.94 95%, CI [0.76-
1.17]).  
 
Table 5. Logistic Regression Analysis between Outcomes of Interest and Primary Predictor 
 Unadjusted Odds Ratio (95% CI) Adjusted Odds Ratio** (95% CI) 
 Common CIMT*  Internal CIMT*  Common 
CIMT*  
Internal CIMT*  
 
2,3-dinor-iPF(2a)-III] 
0.97 (0.91-1.03) 1.01 (0.96-1.06) 0.97 (0.90-1.03) 1.01 (0.92-1.07) 
 
iPF(2a)- III  
0.33 (0.12-0.95) 1.07 (0.49-2.31) 0.32 (0.11-0.97) 0.95 (0.41-2.21) 
 
iPF(2a)- IV  
0.97 (0.93-1.01) 0.98 (0.94-1.02) 0.96 (0.92-1.01) 0.97 (0.93-1.02) 
 
8,12-iso-iPF(2a)-IV  
0.91 (0.85-0.98) 1.00 (0.94-1.05) 0.91 (0.84-0.98) 1.01 (0.92-1.07) 
F2-isoprostane Index  0.77 (0.61-0.98) 1.01 (0.83-1.20) 0.76 (0.58-1.01) 0.94(0.76-1.17) 
 
*Odds ratio (95% CI) 
** Odds ratio adjusted for age, sex, ethnicity, BMI, smoking status, and systolic blood pressure 
 
 
Univariate and Multivariate Linear Regression Analysis 
After natural log transformation of the CCIMT/ICIMT variables the linear regression 
models showed a tendency for inverse association between urinary F2-isoprostanes and 
CCIMT/ICIMT assessing both adjusted and unadjusted parameter estimates (Table 6). The 
logistic and linear models are compatible with each other and indicate that elevated F2-
isoprostanes levels do not predict progress in CCIMT/ICIMT progression. 
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Table 6. Linear Regression Analysis between Outcomes of Interest and Primary Predictor 
 Beta Coefficient estimates for F2-
isoprostane Index (95% CI) 
Adjusted Beta Coefficient estimates for 
F2-isoprostane Index (95% CI) * 
Common 
CIMT  
-0.014(- 0.028 to -0.00028) -0.014( -0.029 to 0.00062) 
Internal 
CIMT  
-0.018(-0.045 to 0.0083) -0.0021 ( -0.030 to 0.026) 
*Adjusted for age, sex, ethnicity, BMI, smoking status, and systolic blood pressure 
 
 
Cardiovascular Disease Sensitivity Analysis 
 
 CVD events were not placed in the adjusted regression analyses due to the fact that 
CVD events are not considered a confounding variable. We cannot use CVD history as a 
confounder, because this is an intermediate variable. We can only do a sensitivity analysis to see 
how our association changes when all previous CVD morbidity is excluded.  As Table 1 shows, 
there are 403 individuals that had a history of CVD at baseline. Once these participants were 
excluded, we ran a logistic regression sensitivity analysis with the remaining 454 participants as 
seen in Table 7. We saw no association between subclinical atherosclerosis progression and F2-
isoprostanes for CCIMT (OR 0.78, 95% CI [0.53-1.15]) and continued to see no association with 
ICIMT (OR 0.98, 95% CI [0.72-1.34]) after adjustment. After examining Tables 5-7 we 
concluded that these findings indicate that elevated levels of urinary F2-isoprostanes do not 
predict subclinical atherosclerosis progression when examining both common and internal 
carotid artery intima-media thickness. 
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Table 7. Logistic Regression Sensitivity Analysis: Excluding those with Baseline CVD Morbidity 
 Unadjusted OR (95% CI) Adjusted OR (95% CI) 
 F2-Isoprostane Index 
Common CIMT  0.76 (0.54-1.06) 0.78 (0.53-1.15) 
Internal CIMT  1.10 (0.84-1.42) 0.98 (0.72-1.34) 
*Adjusted for age, sex, ethnicity, BMI, smoking status, and systolic blood pressure 
 
 
 
 
 
 
 
Discussion 
The present study examined The Insulin Resistance Atherosclerosis Study which 
conducted research on an ethnically and metabolically diverse study population aged 40-69 with 
the goal to understand the association between insulin resistance, cardiovascular disease and its 
risk factors. The diversity makes it generalizable to the US population aged 40-69 and the vast 
data collection of risk factors makes it a suitable study for additional analysis. 
Atherosclerosis is a progressive disease that is responsible for the onset of numerous 
cardiovascular diseases such as stroke, cardiac arrest, and angina. Atherosclerotic cardiovascular 
disease in the leading cause of death worldwide and its burden is expected to continue to rise 
over the next decades, especially in low- and middle-income regions36.  Previous studies have 
demonstrated that there are racial disparities in cardiovascular disease mortality and 
morbidity36,37,37. Studies have shown that non-Hispanic blacks have higher risk of cardiovascular 
disease mortality and morbidity36,37,37. Non-Hispanic blacks are 2 to 3 times more likely to die 
from stroke or heart disease36. The present study also found racial dipartites that aligned with 
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previous studies. Non-Hispanic blacks had the highest level of CCIMT and ICIMT among the 
three groups. At follow up non-Hispanic blacks had a median CCIMT measurement of 0.83 mm, 
compared to non-Hispanic whites (0.80 mm) and Hispanics (0.73). The same disparity was seen 
in ICIMT between non-Hispanic blacks, Hispanics, and non-Hispanic whites (0.85 mm vs 0.77 
mm vs 0.84 mm) respectively.  
Previous studies have also determined that there are disparities in sex for cardiovascular 
disease39,40. There is a 10-year difference between first cardiovascular disease event in women 
compared to men39. Cardiovascular event rates are low in women that are pre-menopausal, and it 
is believed that exposure to endogenous estrogens during earlier stages of life delays the 
manifestation of atherosclerotic disease in women39,40. The current study also saw sex disparities 
in subclinical atherosclerosis between men and women. There was significant difference between 
men and women at follow-up for both median CCIMT (men: 0.83 mm vs women:0.76 mm, 
p<.0001) and median ICIMT (men:0.87 mm vs women:0.79 mm, p<.0001). 
 One major risk factor for atherosclerosis is diabetes. Adults with diabetes are two to four 
times more likely to die from heart disease than adults without diabetes42. About 68% of people 
65 years of age are older who have diabetes die from heart disease and 16% die from storke42. It 
is believed that this association between diabetes and cardiovascular disease has to do with the 
role hyperglycemia plays in the pathogenesis of atherosclerosis41,42,44. The present analysis using 
IRAS data also saw a significant difference (p<0.0001) through an impaired glucose tolerance 
gradient. At follow-up those with normal glucose tolerance had the lowest median CCIMT (0.76 
mm) followed by those with impaired glucose tolerance (0.80 mm), and diabetes (0.84 mm). The 
same gradient between the three groups was seen in ICIMT as well (0.80 mm vs 0.83 mm vs 
0.88 mm, p<0.001). 
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Although there have been studies indicating that reactive oxygen species play an 
important role in the pathology of many chronic diseases including cardiovascular disease14,33,58, 
based on results from this study, the typical way of thinking about the relationship between F2-
isoprostanes and cardiovascular disease may not be completely accurate. Reactive oxygen 
species are believed to play an important role in the pathology of cardiovascular disease 
progression however previous randomized clinical trials of antioxidants failed to conclude any 
beneficial effects of antioxidant intake on cardiovascular disease morbidity or mortality22,23. The 
present study examined urinary F2-isoprostanes, a reliable measure of ROS and oxidative status, 
and did not see a direct association between subclinical atherosclerosis progression and increased 
levels of systemic F2-isoprostanes when examining biomarkers for subclinical atherosclerosis 
CCIMT (OR  = 0.76) and ICIMT (OR = 0.94) after adjustment.  Based on this study, it seems that 
high level of F2-isoprostanes are not associated with progression in subclinical atherosclerosis. 
The inverse association between CCIMT progression and F2-isoprostane levels is the opposite of 
what is expected based on previous studies,33,58.  
Although direct correlation of F2-isoprostanes with cardiovascular disease is the more 
traditional way of thinking, another biological hypothesis about F2-isoprostanes that would align 
with the results shown in this study is that F2-isoprostanes are possible markers for fatty acid 
oxidation, mitochondrial metabolism, in addition to markers for reactive oxygen species levels. 
There have been studies on conditions that have to do with intense fat oxidation such as fasting 
and exercise that showed a direct correlation with increase F2-isoprostanes45. Steensberg, et al. 
noted that F2-isoprostanes increased approximately 1.6-fold in response to moderate exercise44.  
Additionally, Il’yasova, et al. showed a direct correlation between C2 and C12, which are 
metabolic markers of fatty acid oxidation and F2-isoprostanes, adjusted beta coefficients are 
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0.109 and 0.072 respectively, giving more evidence to the theory of F2-isoprostanes being 
markers of mitochondrial fatty acid oxidation29. 
  As table 4 shows ethnicity is associated with F2-isoprostanes with non-Hispanic blacks 
having the lowest F2-isoprostane index ( -0.43ng/mg creatinine) followed by non-Hispanic 
whites and Hispanics (-0.25 ng/mg creatinine, 0.008 ng/mg creatinine) respectively. These 
findings align with previous findings that showed non-Hispanic blacks, who are known to have 
slower mitochondrial oxidation as well as lower levels of fat oxidation, also had lower levels of 
systemic F2-isoprostanes compared to non-Hispanic whites34 further suggesting that F2-
isoprostanes are possible markers of positive mitochondrial activity and not necessarily just 
markers of harmful oxidative damage.   
F2-isoprostanes are markers of free radical oxidative stress and although free radical 
oxidative stress may not be associated with cardiovascular disease risk, it does not mean that the 
idea of oxidative stress being an important part of cardiovascular disease pathology is wrong. 
Recent evidence has shown that non-free radical marker of oxidative stress; plasma aminothiols, 
high cystine levels, and low glutathione, were associated with coronary heart disease56. 
Additionally, a study by Dhawan, et al. presented evidence that lower plasma glutathione levels 
(r=0.39, p=0.01) as well as higher cystine/glutathione ratio (r=-0.29, p=0.04) were independent 
predictors of impaired coronary microvascular function which can lead to higher susceptibility to 
atherosclerosis 56. Plasma aminothiols such as cysteine, cysteinyl glycine, and glutathione are 
considered good non-free radical markers for oxidative stress58.  All of these species interreact 
through the thiol redox status which plays an important role in redox homeostasis. Redox 
homeostasis is an important condition for normal cellular function58. When excessive amounts of 
total plasma homocysteine and cysteine are produced or when low levels of glutathione are 
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produced it can result in pro-oxidant effects58. Some known effects of redox homeostasis 
imbalance include endothelial dysfunction as well as LDL oxidation which can result in the onset 
of atherosclerosis58. Evidence has shown that both high plasma homocysteine and cysteine levels 
as well as low glutathione levels are well known conditions associated with atherosclerosis and 
CVD58-60. 
It could be hypothesized that free radical oxidative stress may be related to mitochondria 
activity and fatty acid oxidation, while non-free radical oxidative stress is more relevant to the 
development of atherosclerosis and cardiovascular disease. Therefore, it would be expected that 
F2-isoprostanes would show no signs of association with atherosclerosis and would possibly be a 
maker of decrease risk if F2-isoprostanes were markers of fatty acid oxidation. Non-free radical 
oxidative stress markers, such as plasma thiols, may be a more important factor in atherosclerosis 
progression and CVD events. Future studies are needed to get a better understanding of the 
different forms of oxidative markers and their influence on different diseases.   
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                                                Conclusion 
 
The result from this study indicate that urinary F2-isoprostanes do not predict progress in 
subclinical atherosclerosis when examining CCIMT (OR 0.76, 95% CI 0.58-1.01) and ICIMT 
(OR 0.94, 95% CI 0.76-1.17). The CVD sensitivity analysis performed also indicated that F2-
isoprostanes do not predict progress in subclinical atherosclerosis when examining CCIMT (OR 
0.78, 95% CI 0.53-1.15) and ICIMT (OR 0.98, 95% CI 0.72-1.34) after excluding participants 
with previous CVD history. Although these finding contradict with the typical way of viewing 
the relationship between F2-isoprostanes and atherosclerosis, the findings may align with the 
theory that F2-isoprostanes levels, reactive oxygen species levels, and mitochondrial fatty acid 
oxidation are intertwined. More research should be dedicated to understanding the role free 
radical oxidative markers and non-free radical oxidative markers play in the pathology of 
cardiovascular disease so a conclusive understanding of the relationship between oxidative status 
and CVD can be attained. Additionally, research focused on F2-isoprostanes as makers of 
mitochondrial fatty acid oxidation is needed to gain a better understanding of this hypothesis. 
Due to the severity of CVD mortality and morbidity in so many countries, it is vital to 
understand the important pathological steps of its main cause, atherosclerosis formation, in an 
effort to create early detection methods that can serve as primary prevention measures for 
cardiovascular events.  
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